Clinical Trial

A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-28.
Trial Details
NCT Number NCT06954961
Lead Sponsor InventisBio Co., Ltd
Conditions Breast Cancer
Enrollment 640 participants
Start Date 2022-09-15
Primary Completion 2026-11-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-31